Trial Profile
Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL): A Phase II Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 15 Aug 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.
- 15 Aug 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2024.
- 22 Feb 2023 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.